This Series paper reviews thalassaemia prevention across 14 Asian countries with high carrier frequencies, heterogeneous mutations, and unequal health-system capacity. Singapore, Malaysia, the Maldives, and Thailand had the most structured approaches, combining public awareness, carrier screening, genetic counselling, and prenatal diagnosis. Measurable success was clearest in Singapore and to a more limited extent Thailand. Many countries still face fragmented services, weak national coordination, workforce shortages, insufficient epidemiological data, and financial, technological, cultural, and social barriers. This is a regional health-system synthesis, not a comparative policy trial.
Key findings
- Singapore, Malaysia, the Maldives, and Thailand were identified as having the most structured prevention strategies among the reviewed countries.
- Measurable prevention success was clearest in Singapore and demonstrated to a specific extent in Thailand.
- Recurring regional barriers included fragmented services, weak coordination and data, workforce shortages, cost, technology, and cultural and social constraints.
Why this matters globally
Severe thalassaemia creates lifelong treatment needs, so voluntary, informed, non-directive, and equitable prevention programmes may reduce family and health-system burden. Regional cooperation on standards, data, and workforce could help, but every country must adapt programmes to reproductive rights, culture, law, and resources rather than copy a single model.
Thai researcher contribution
Suthat Fucharoen and Kittiphong Paiboonsukwong of Mahidol University's Thalassemia Research Center contributed Thailand's regional experience; Fucharoen also held an affiliation with Samitivej Srinakarin Hospital. The review positions Thai screening, counselling, and prenatal diagnosis as a comparative Asian case while acknowledging that success remains partial.
Limitations to consider
This Series review combines country evidence with different years, definitions, coverage, and quality. It is not a systematic review or meta-analysis and lacks one standardized outcome set across 14 countries. Data availability and expert perspective may shape judgments, national summaries can hide subnational inequity, and programme effects cannot be separated from broader health-system development.